138 related articles for article (PubMed ID: 37981300)
1. BRAF V600E-mutated Colorectal Neuroendocrine Carcinoma Effectively Treated with a Chemotherapy Protocol for BRAF-mutated Metastatic Colorectal Cancer: A Case Report.
Owaki S; Mori Y; Nakai S; Maeda H; Imazu M; Tomita Y; Kanaiwa H; Yamaguchi A; Kitagawa M; Hirano A; Kimura Y; Tsuchida K; Kataoka H
Intern Med; 2023 Nov; ():. PubMed ID: 37981300
[TBL] [Abstract][Full Text] [Related]
2. Conversion Surgery After Encorafenib Plus Cetuximab for Chemorefractory
Kawata A; Miyamoto Y; Fukubayashi K; Horio T; Miyamoto H; Ogawa K; Ouchi M; Tanaka Y; Baba H
In Vivo; 2023; 37(4):1797-1801. PubMed ID: 37369457
[TBL] [Abstract][Full Text] [Related]
3. TRESBIEN (OGSG 2101): encorafenib, binimetinib and cetuximab for early recurrent stage II/III
Boku S; Satake H; Ohta T; Mitani S; Kawakami K; Suzuki Y; Matsumoto T; Terazawa T; Yamazaki E; Hasegawa H; Ikoma T; Uemura M; Yamaguchi T; Naito A; Ishizuka Y; Kurokawa Y; Sakai D; Kawakami H; Shimokawa T; Tsujinaka T; Kato T; Satoh T; Kagawa Y
Future Oncol; 2022 Dec; 18(38):4153-4160. PubMed ID: 36475784
[TBL] [Abstract][Full Text] [Related]
4. Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience.
Boccaccino A; Borelli B; Intini R; Antista M; Bensi M; Rossini D; Passardi A; Tamberi S; Giampieri R; Antonuzzo L; Noto L; Roviello G; Zichi C; Salati M; Puccini A; Noto C; Parisi A; Rihawi K; Persano M; Crespi V; Libertini M; Giordano M; Moretto R; Lonardi S; Cremolini C
ESMO Open; 2022 Jun; 7(3):100506. PubMed ID: 35696748
[TBL] [Abstract][Full Text] [Related]
5.
Imai T; Shoji H; Hirano H; Matsuguma K; Awatsu T; Hirose T; Okita N; Takashima A; Kato K
CNS Oncol; 2024 Jun; 13(1):2347824. PubMed ID: 38869444
[TBL] [Abstract][Full Text] [Related]
6. [A Case of BRAF V600E-Mutant Colorectal Cancer Treated Effectively by Encorafenib, Binimetinib, and Cetuximab Triple Therapy].
Sakamoto S; Tagai N; Shimada M; Kurebayashi H; Sawai K; Morikawa M; Koneri K; Tamaki M; Murakami M; Hirono Y; Goi T
Gan To Kagaku Ryoho; 2022 Oct; 49(10):1145-1147. PubMed ID: 36281614
[TBL] [Abstract][Full Text] [Related]
7. Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines.
Grothey A; Fakih M; Tabernero J
Ann Oncol; 2021 Aug; 32(8):959-967. PubMed ID: 33836264
[TBL] [Abstract][Full Text] [Related]
8. VIC Regimen (Vemurafenib/Irinotecan/Cetuximab) Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Unresectable or Metastatic Colorectal Cancer in Asian Patients: A Prospective Cohort Study.
Chen Y; Zhu D; Yu Y; Chang W; Ye L; Feng Q; Xu P; Chen M; Ji M; Wei Y; Liu T; Xu J
Clin Colorectal Cancer; 2024 May; ():. PubMed ID: 38845274
[TBL] [Abstract][Full Text] [Related]
9. FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of
Stintzing S; Heinrich K; Tougeron D; Modest DP; Schwaner I; Eucker J; Pihusch R; Stauch M; Kaiser F; Kahl C; Karthaus M; Müller C; Burkart C; Reinacher-Schick A; Kasper-Virchow S; Fischer von Weikersthal L; Krammer-Steiner B; Prager GW; Taieb J; Heinemann V
J Clin Oncol; 2023 Sep; 41(25):4143-4153. PubMed ID: 37352476
[TBL] [Abstract][Full Text] [Related]
10. Encorafenib, Binimetinib, and Cetuximab in
Kopetz S; Grothey A; Yaeger R; Van Cutsem E; Desai J; Yoshino T; Wasan H; Ciardiello F; Loupakis F; Hong YS; Steeghs N; Guren TK; Arkenau HT; Garcia-Alfonso P; Pfeiffer P; Orlov S; Lonardi S; Elez E; Kim TW; Schellens JHM; Guo C; Krishnan A; Dekervel J; Morris V; Calvo Ferrandiz A; Tarpgaard LS; Braun M; Gollerkeri A; Keir C; Maharry K; Pickard M; Christy-Bittel J; Anderson L; Sandor V; Tabernero J
N Engl J Med; 2019 Oct; 381(17):1632-1643. PubMed ID: 31566309
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness Analysis of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Metastatic Colorectal Cancer in the USA.
Li S; Hu H; Ding D; Zhu Y; Huang J
Adv Ther; 2021 Mar; 38(3):1650-1659. PubMed ID: 33569738
[TBL] [Abstract][Full Text] [Related]
12. Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC.
Kopetz S; Grothey A; Van Cutsem E; Yaeger R; Wasan H; Yoshino T; Desai J; Ciardiello F; Loupakis F; Hong YS; Steeghs N; Guren TK; Arkenau HT; Garcia-Alfonso P; Belani A; Zhang X; Tabernero J
ESMO Open; 2022 Jun; 7(3):100477. PubMed ID: 35653981
[TBL] [Abstract][Full Text] [Related]
13. NEXUS trial: a multicenter phase II clinical study evaluating the efficacy and safety of the perioperative use of encorafenib, binimetinib, and cetuximab in patients with previously untreated surgically resectable BRAF V600E mutant colorectal oligometastases.
Kobayashi S; Bando H; Taketomi A; Takamoto T; Shinozaki E; Shiozawa M; Hara H; Yamazaki K; Komori K; Matsuhashi N; Kato T; Kagawa Y; Yokota M; Oki E; Komine K; Takahashi S; Wakabayashi M; Yoshino T
BMC Cancer; 2023 Aug; 23(1):779. PubMed ID: 37605122
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study.
Eriksen M; Pfeiffer P; Rohrberg KS; Yde CW; Petersen LN; Poulsen LØ; Qvortrup C
BMC Cancer; 2022 Dec; 22(1):1321. PubMed ID: 36527039
[TBL] [Abstract][Full Text] [Related]
15. Pancreatitis After Treatment With Encorafenib, Binimetinib, and Cetuximab for BRAF V600E Mutation-Positive Colorectal Cancer.
Kureyama Y; Hanaoka Y; Tomita D; Matoba S; Kuroyanagi H
Cureus; 2024 May; 16(5):e60188. PubMed ID: 38741697
[TBL] [Abstract][Full Text] [Related]
16. Complete response with fluorouracil and irinotecan with a BRAF
Wang Z; Dai WP; Zang YS
Onco Targets Ther; 2019; 12():443-447. PubMed ID: 30662270
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study.
Wang X; Wei Q; Gao J; Li J; Li J; Gong J; Li Y; Shen L
Chin J Cancer; 2017 Oct; 36(1):81. PubMed ID: 29037218
[TBL] [Abstract][Full Text] [Related]
18.
Ros J; Baraibar I; Sardo E; Mulet N; Salvà F; Argilés G; Martini G; Ciardiello D; Cuadra JL; Tabernero J; Élez E
Ther Adv Med Oncol; 2021; 13():1758835921992974. PubMed ID: 33747149
[TBL] [Abstract][Full Text] [Related]
19. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated
Tabernero J; Grothey A; Van Cutsem E; Yaeger R; Wasan H; Yoshino T; Desai J; Ciardiello F; Loupakis F; Hong YS; Steeghs N; Guren TK; Arkenau HT; Garcia-Alfonso P; Elez E; Gollerkeri A; Maharry K; Christy-Bittel J; Kopetz S
J Clin Oncol; 2021 Feb; 39(4):273-284. PubMed ID: 33503393
[TBL] [Abstract][Full Text] [Related]
20. Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer.
Al-Marrawi MY; Saroya BS; Brennan MC; Yang Z; Dykes TM; El-Deiry WS
Cancer Biol Ther; 2013 Aug; 14(8):703-10. PubMed ID: 23792568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
